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Purpose: Trauma and complex cardiac surgery are
associated with a high risk of bleeding complications.
The difference in costs between patients who require
bleeding control measures and those who do not is
poorly understood. Our goal was to assess the cost of
care and outcomes for patients in these settings.
Methods: Patients 418 years of age, who were
discharged between January 2010 and December
2012, were retrospectively identiﬁed in the Premier
Hospital Database based on International Classiﬁca-
tion of Disease, Ninth Revision codes. These patients
were categorized as having received blood products
(“bleeding patients”) or not (“nonbleeding patients”).
Patients with costs and length of stay (LOS) of zero
were excluded. Differences in treatment costs and
outcomes were assessed using univariate analysis
and multivariate modeling.
Findings: Bleeding trauma patients (n ¼ 8800) had a
150% higher total cost of care (P o 0.001; 146%
after excluding costs of agents used for bleeding control,
Po 0.001), an 81.3% longer hospital LOS (Po 0.001),
and a 65.2% longer intensive care unit (ICU) LOS
(P o 0.001) than nonbleeding patients (n ¼ 53,727).
Bleeding complex cardiac surgery patients (n ¼ 82,832)
had a 133.2% higher total cost of care (P o 0.001;
128.7% after excluding costs of agents used for bleeding
control, P o 0.001), a 155.6% longer hospital LOS
(P o 0.001), and an 89.3% longer ICU LOS
(P o 0.001) than nonbleeding patients (n ¼ 380,902).
Implications: Trauma and cardiac surgery patients
who experienced bleeding and received allogeneic
blood product transfusions had signiﬁcantly worse
outcomes, including longer LOS, greater inpatient
mortality, and higher costs of care (even when
excluding costs of agents used for bleeding control)
than those who did not. (Clin Ther. 2015;37:1966–
1974) & 2015 The Authors. Published by Elsevier
HS Journals, Inc.
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patient outcomes, pharmacoeconomics, trauma.1966INTRODUCTION
The true cost of allogeneic blood products, such as
fresh frozen plasma (FFP), red blood cells (RBCs), and
cryoprecipitate, is an issue that is poorly understood
and not well documented in the literature.1 It is a
complex matter, because costs have to take into
account not only the direct acquisition cost of the
product, but also the associated indirect costs, such as
blood collection, testing, distribution, and storage.2
Furthermore, the total cost should also take into
account all costs associated with hospital stay and
the treatment of any adverse events and poor
outcomes associated with blood product transfusion.
Blood products have been associated with a number of
adverse events, including transfusion-associated circu-
latory overload (TACO), transfusion-related acute
lung injury (TRALI), pathogen transmission, allergic
reactions, and even increased mortality,3–5 and there is
a dose-dependent correlation between allogeneic
blood product transfusion and adverse outcomes in
trauma patients.6 Patients who receive allogeneic
blood product transfusions have been shown to
require longer hospital stays,6 which signiﬁcantly
increases the cost of their treatment; it has been
estimated that hospital stay accounts for 465% of
all transfusion-related costs.7
In addition, the cost of blood products themselves
is rising. This can be attributed to a number of factors,
including increased demand, tighter restrictions on
blood donor eligibility, and increasing laboratory
testing and treatment of blood to keep it free from
infectious diseases and bacteria.2,8,9 For example, the
introduction of pathogen reduction technology, such
as treatment of plasma with amotosalen or riboﬂavin,
can more than triple the cost of a unit of blood.10Volume 37 Number 9
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trauma are known to be associated with high rates of
transfusion. Up to 15% of the US blood supply is
transfused in the setting of cardiac surgery,11 and
approximately 1 in 10 trauma patients experience
signiﬁcant hemorrhaging,12 which results in a high
transfusion rate in this setting. Hemorrhage is
associated with poor outcomes, such as increased
morbidity, mortality, and even death,13–15 which leads
to an increased use of resources by these patients
during hospitalization.
To determine the cost implications of allogeneic blood
product transfusion in trauma and complex cardiac
surgery, we assessed the cost of care and outcomes for
patients in these 2 clinical settings based on bleeding
status (ie, bleeding patients vs nonbleeding patients).
PATIENTS AND METHODS
Trauma and Cardiac Surgery
In this retrospective analysis, patients 418 years
old discharged between January 1, 2010 and Decem-
ber 31, 2012 were identiﬁed in the US Premier
Hospital Database based on select International Clas-
siﬁcation Disease, Ninth Revision (ICD-9) procedure
codes within the trauma or complex cardiac surgical
population deﬁnitions (Appendix). The Premier
Hospital Database is a Health Insurance Portability
and Accountability Act compliant dataset and is
considered exempt from approval from an
institutional review board based upon the Code of
Federal Regulation, §46.101b(4), from the United
States Department of Health and Human Services.
Complex cardiac patients included those who
underwent operations of the valves, septa, or vessels
of the heart, as well as those with incision or excision
of the aorta or other thoracic vessels. Trauma patients
included those with a diagnosis code that indicated
internal injuries to the heart, lung, or other speciﬁed
internal organs. A listing of the codes used to identify
patients is presented in the Appendix. Patients were
then categorized as bleeding or nonbleeding, based on
speciﬁc ICD-9 codes and blood product use (patients
who received at least 1 U of blood products [RBCs,
FFP, cryoprecipitate, or platelets] were characterized
as bleeding). Use of the following agents for bleeding
control was extracted from the database: RBCs, FFP,
platelets, cryoprecipitate, recombinant activated factor
VII, and hetastarch. Patients who received blood
products before the day of surgery or patients withSeptember 2015costs and a hospital length of stay (LOS) of zero were
excluded. The following information relating to pa-
tient demographic characteristics was extracted from
the database: age, gender, race, ethnicity, comorbid-
ities and comorbidity score, and hospital costs. Prod-
ucts and services that might have inﬂuenced the use of
blood products in bleeding patients, including ﬁbrin
sealants, tranexamic acid, protamine, and the use of
an intraoperative cell saver, were identiﬁed and used
as effect modiﬁers in multivariate analyses. All costs
were based on hospital-reported costs for procedures,
medications, other therapies, and laboratory costs
taken directly from chargemaster-detailed use.
The primary outcome was hospital cost per patient
(both including and excluding costs of agents used for
bleeding control); secondary outcomes included hospital
LOS, intensive care unit (ICU) admission and LOS,
inpatient mortality, hospital readmission, and adverse
events (including TACO, TRALI, thromboembolic
events, pulmonary edema, and acute respiratory distress).
Statistical Analysis
Differences in outcomes between bleeding and
nonbleeding patients were assessed using both uni-
variate analysis and multivariate regression models.
Statistical signiﬁcance for univariate comparisons was
assessed using χ2 tests for categorical variables and
Student’s t tests for continuous variables. Multivariate
analysis was used to calculate odds ratios for inpatient
mortality, 30-day readmission for bleeding, and ICU
admission; conﬁdence limits for these parameters were
generated using the Wald test. A fully speciﬁed model
was developed that included all covariates that dem-
onstrated signiﬁcant differences in univariate compar-
isons from patient demographic and hospital
characteristic variables, as well as the Charlson Co-
morbidity Index score and ICU admission. All models
used backward elimination with a P value ofo 0.1 to
determine variable inclusion in the ﬁnal model.
RESULTS
Trauma
A total of 62,527 trauma patients were identiﬁed
for inclusion in the study; of these, 8800 received at
least 1 U of blood products (bleeding patients), and
53,727 did not (nonbleeding patients). Baseline pa-
tient characteristics are shown in Table I.
In the bleeding patients group, 56.2% (n ¼ 4942)
of patients received RBCs (mean [SD] 4.8 [6.7] U),1967
Clinical Therapeutics44.3% (n ¼ 3893) received FFP (mean 6.4 [10.1] U),
2.7% (n ¼ 240) received cryoprecipitate (mean 9.6
[2.9] U), and 13.5% (n ¼ 1180) received platelets
(mean 2.9 [3.9] U). Mean costs for these blood
products per transfused patient were $1112 for RBCs,
$578 for FFP, $1463 for cryoprecipitate, and $1486
for platelets (Table II).
Multivariate models adjusting for patient demo-
graphic characteristics demonstrated that, when the
costs of agents used for bleeding control were in-
cluded, bleeding patients had a 150% higher total cost
of care ($46,033 vs $18,434; P o 0.001) than non-
bleeding patients (Figure 1; Table III). When the costs
of agents used for bleeding control were excluded,
bleeding patients had a 146% higher total cost of care
($45,375 vs $18,441; P o 0.001).
Bleeding patients had a 81.3% longer LOS (13.6
days vs 7.5 days; P o 0.001). They were also 3.53
times as likely to be admitted to the ICU (Po 0.001),
3.75 times as likely to be readmitted for bleeding
within 30 days (P o 0.001), and 4.09 times as likely
to die in hospital (P o 0.001). The mortality rateTable I. Baseline characteristics of trauma and complex
Trauma
Characteristic
Nonbleeding
Patients
(n ¼ 53,727)
Bleeding
Patients
(n ¼ 8800) P
Gender, n (%)
Female 13,764 (25.6) 2461 (28.0) o
Male 39,947 (74.4) 6329 (71.9)
Unknown 16 (0.0) 10 (0.1)
Age, y, mean (SD) 55.8 (22.7) 54.4 (22.7) o
Race, n (%)
Black 7242 (13.5) 1142 (13.0)
White 35,408 (65.9) 5715 (64.9)
Other 11,077 (20.6) 1943 (22.1)
Ethnicity, n (%)
Hispanic 1348 (2.5) 271 (3.1)
Non-Hispanic 42,650 (79.4) 6857 (77.9)
Other 9729 (18.1) 1672 (19.0) o
CCI score, mean
(SD) [median]
1.3 (2.0) [0] 1.4 (2.0) [0]
CCI ¼ Charlson Comorbidity Index.
1968differed signiﬁcantly between the 2 groups (10.72%
bleeding patients vs 3.14% nonbleeding patients; Po
0.001). Compared with nonbleeding patients, bleeding
patients had higher rates of thromboembolic events
(7.84% vs 6.70%; P o 0.001), TACO (2.00% vs
0.76%; P o 0.001), and TRALI (0.13% vs 0.01%;
Po 0.001). The incidence of acute respiratory distress
did not differ between the 2 groups (0.31% vs 0.33%;
P ¼ 0.730), and no cases of pulmonary edema were
observed in either group.
Cardiac Surgery
A total of 463,734 patients (82,832 bleeding;
380,902 nonbleeding) were included. Baseline demo-
graphic patient characteristics are shown in Table I.
Bleeding patients were older (465 years: 62.3% vs
49.8%; P o 0.001), sicker (Charlson Comorbidity
Index 43: 22.5% vs 15.4%; P o 0.001), and had
higher rates of cerebrovascular disease (10.2% vs
4.3%; P o 0.001) and peripheral vascular disease
(18.2% vs 9.4%; P o 0.001) than nonbleeding
patients.cardiac surgery patients
Complex Cardiac Surgery
Value
Nonbleeding
Patients
(n ¼ 380,902)
Bleeding
Patients
(n ¼ 82,832) P Value
0.001 122,739 (32.2) 30,399 (36.7) o0.001
258,125 (67.8) 52,403 (63.3)
38 (0.0) 30 (0.0)
0.001 64.3 (12.3) 67.4 (11.9) o0.001
30,753 (8.1) 5894 (7.1) o0.001
0.005 271,218 (71.2) 59,047 (71.3)
78,931 (20.7) 17,891 (21.6)
5838 (1.5) 1166 (1.4) o0.001
301,971 (79.3) 64,941 (78.4)
0.001 73,093 (19.2) 16,725 (20.2)
0.005 1.9 (1.7) [1] 2.3 (1.9) [2] o0.001
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Table II. Agents used for bleeding control in trauma and complex cardiac surgery patients
Trauma Complex Cardiac Surgery
Characteristics
Nonbleeding Patients
(n ¼ 53,727) Bleeding Patients (n ¼ 8800)
Nonbleeding Patients
(n ¼ 380,902) Bleeding Patients (n ¼ 82,832)
n
(%)
Mean (SD) Median
Cost per Recipient
($) n (%)
Mean (SD) Median
Dose per Recipient
(U)
Mean (SD) Median
Cost per Recipient
($) P Value n (%)
Mean (SD) Median
Cost per Recipient
($) n (%)
Mean (SD) Median
Dose per Recipient
(U)
Mean (SD) Median
Cost per Recipient
($) P Value
PRBCs — — 4942
(56.2)
4.81 (6.65) 3.0 1112 (2001) 582 — — 42,691
(51.5)
4.51 (4.90) 3.0 1034 (1450) 627
FFP — — 3893
(44.3)
6.43 (10.08) 4.0 578 (1183) 252 — — 30,118
(36.4)
4.22 (5.45) 0.0 323 (591) 192
Platelets — — 1180
(13.5)
2.89 (3.91) 2.0 1486 (2427) 742 — — 22,914
(27.7)
2.95 (4.77) 0.0 1281 (1583) 830
Cryoprecipitate — — 240
(2.7)
9.64 (12.72) 7.0 1463 (2295) 759 — — 4892
(5.9)
5.53 (6.81) 5.0 968 (1481) 563
rFVIIa — — 190
(2.2)
5.77 (6.49) 3.5 7549 (8352) 4895 — — 1551
(1.9)
4.91 (6.65) 3.0 7349 (14,691) 4453
Hetastarch — — 1264
(14.4)
1.67 (1.50) 1.0 51 (77) 29 — — 25,148
(30.4)
1.74 (1.47) 1.0 45 (54) 30
Fibrin sealants 128
(0.2)
97
(1.1)
— o0.001 2320
(0.6)
2474
(3.0)
— o0.001
600 (430) 513 897 (1066) 676 0.011 581 (446) 507 669 (601) 505 o0.001
Tranexamic
acid
39
(0.1)
52
(0.6)
— o0.001 1472
(0.4)
2187
(2.6)
— o0.001
168 (202) 111 255 (421) 147 0.200 452 (318) 531 193 (254) 67 o0.001
Protamine 420
(0.8)
341
(3.9)
— o0.001 58,470
(15.4)
55,575
(67.1)
— o0.001
23 (25) 14 30 (38) 20 0.002 36 (35) 27 38 (41) 27 o0.001
Intraoperative
cell saver
375
(0.7)
506
(5.8)
— o0.001
0.462
24,377
(6.4)
26,928
(32.5)
— o0.001
385 (637) 150 422 (849) 152 495 (803) 228 415 (653) 215 o0.001
FFP ¼ fresh frozen plasma; PRBCs ¼ packed red blood cells; rFVIIa ¼ recombinant activated factor VII.
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1970In the bleeding patients group, 51.5% (n ¼ 42,691)
of patients received RBCs (mean [SD] 4.5 [4.9] U),
36.4% (n ¼ 30,118) received FFP (mean 4.2 [5.5] U),
5.9% (n ¼ 4892) received cryoprecipitate (mean 5.5
[6.8] U), and 27.7% (n ¼ 22,914) received platelets
(mean 3.0 [4.8] U). Mean costs for these blood
products per transfused patient were $1034 for RBCs,
$323 for FFP, $968 for cryoprecipitate, and $1281 for
platelets (Table II).
Multivariate models that adjusted for patient dem-
ographic characteristics demonstrated that, in bleed-
ing patients, the total cost of hospital stay was
133.2% higher when the costs of agents used for
bleeding control were included ($50,344 vs $21,590;
Po 0.001) and 128.7% higher when these costs were
excluded ($49,378 vs $21,590; P o 0.001) than in
nonbleeding patients (Figure 1; Table III).
Bleeding patients were 4.54 times as likely to be
admitted to the ICU, 3.40 times as likely to die, and
4.59 times as likely to be readmitted for bleeding
within 30 days (all P o 0.001). They also had a
49.1% longer hospital LOS (P o 0.001) than non-
bleeding patients. Mortality was signiﬁcantly higher in
bleeding patients than in nonbleeding patients (5.30%
vs 1.43%; P o 0.001). Bleeding patients also experi-
enced higher rates of a number of adverse events,
including TACO (6.38% vs 1.80%; P o 0.001),
TRALI (0.07% vs 0.01%; P o 0.001), and acute
respiratory distress (0.36% vs 0.22%; P o 0.001). In
contrast, more nonbleeding patients experienced
thromboembolic events than bleeding patients
(46.12% vs 29.92%; P o 0.001).
DISCUSSION
Our study showed that, in the settings of both trauma
and complex cardiac surgery, bleeding patients had
signiﬁcantly worse outcomes than nonbleeding
patients. Bleeding patients had longer hospital and
ICU LOS, greater inpatient mortality, and higher total
costs of care, even when the costs of agents used for
bleeding control were excluded. In addition, bleeding
patients were more likely to be readmitted to the
hospital than nonbleeding patients.
The true total cost of allogeneic blood products is
difﬁcult to deﬁne, because it must take into account all
aspects of the blood collection, production, and
administration process. A 2007 study by Shander
et al.2 suggested that there were 9 cost areas that
must be taken into account, ranging from the costsVolume 37 Number 9
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Figure 1. Comparison of total hospital costs for bleeding and nonbleeding patients in trauma and complex
cardiac surgery.
A. Zbrozek and G. Mageeincurred by blood donors to the cost of organizing
and maintaining nationwide and/or international
hemovigilance programs. The authors estimated that,
taking into account only 3 of the 9 described cost
elements (cost of producing blood components for
transfusion, transfusion logistics, and the treatment of
transfusion-transmitted disease and associated adverse
outcomes), the real cost of blood per unit in 2007 was
a minimum of $1400.2 Other estimates for the price of
blood components per unit have ranged from $350.49
to $780.59.16–18 However, the costs are difﬁcult to
compare across studies, because each of these studies
was performed in a different clinical setting, and
varying methods were used to calculate the total.
A large proportion of the total cost of blood
products can be attributed to costs incurred post-
transfusion, such as the treatment of adverse events
and hospital LOS. On average, bleeding patients in the
present study stayed in hospital for 4 days longer than
nonbleeding patients, an increase in LOS of 38.9%.
Of the patients who were admitted to the ICU,
bleeding patients stayed an average of 2 days longer
than nonbleeding patients. The impact of transfusion
on hospital LOS was shown previously, with 1 UK
study estimating that hospital LOS accounted for
66% of total costs.7 A 2008 study of patients withSeptember 2015acute coronary syndrome found that total treatment
costs per patient increased by $2080 for each
transfusion event.19 Further analysis of these data
showed that the majority of this increased cost could
be attributed to increased hospital LOS. Another
economic study of patients who underwent
colorectal cancer resection showed that total hospital
charges of transfused patients were signiﬁcantly higher
than those of nontransfused patients ($28,101 vs
$15,978; P o 0.0001), and that charges were
shown to increase by 2.0% per unit of RBCs and/or
platelets transfused after adjustment for confounding
factors.20 In addition, hospital LOS was signiﬁcantly
longer in the transfused group (16.7 days vs 10.3
days; P o 0.0001), and was shown to increase by
1.3% for every unit of RBCs and/or platelets
transfused.
A number of previous studies showed that the
transfusion of allogeneic blood products is associated
with a number of adverse events, including TACO,
TRALI, allergic reactions, and the transmission of
pathogens.4,21–23 In the present study, bleeding car-
diac surgery and trauma patients who received trans-
fusions experienced signiﬁcantly higher rates of
TACO and TRALI than those who did not receive
tranfusions. Studies showed that avoidance of blood1971
Clinical Therapeuticsproduct transfusion reduced the risk of complica-
tions,24 and although data are limited, patient blood
management programs were shown to reduce
transfusion and improve patient outcomes.25 One
recent study showed that the implementation of a
blood product conservation initiative in the setting of
cardiac surgery reduced postoperative morbidity and
mortality, reduced health care costs, and improved
resource utilization.26 Furthermore, the implemen-
tation of hemostatic therapy algorithms based on
point-of-care (POC)-guided coagulation management
was shown to reduce blood product transfusion in
different clinical settings.27–30 In the setting of cardiac
surgery, one such study compared a POC-guided
algorithm with conventional therapy (whereby hemo-
static therapy was driven by laboratory coagulation
testing).27 Patients randomized to the POC algorithm
group received fewer FFP and platelet transfusions,
had shorter ICU LOS, experienced fewer adverse
events, and had a lower mortality rate than patients
in the conventional therapy group.27
Therefore, we hypothesize that the use of patient
blood management strategies may improve clinical
outcomes by focusing not only on the reduction of
blood product transfusion, but also on minimizing
blood loss.25 Preoperatively, this consists of
identifying patients at risk of bleeding as soon as
possible, and ensuring any necessary treatment is
promptly administered. Intraoperatively, the use of
meticulous hemostasis, surgical, and anesthetic
techniques can all help to minimize blood loss. For
example, maintaining physiologic body temperature
during surgery can reduce blood loss and transfusion
requirements.31,32 Goal-directed therapy can reduce
postoperative blood loss,28 and when used in
combination with a transfusion algorithm, POC-
guided coagulation therapy in the setting of cardiac
surgery has been shown to reduce both transfusion
requirements and costs.28,33,34
Our study had limitations similar to other obser-
vational studies. ICD-9 codes were used to determine
patient inclusion; identiﬁcation of comorbidities and
coding practices might differ among hospitals. Sim-
ilarly, data regarding use and costs relies on hospitals
reporting from their chargemaster records. Finally,
our results only considered the variables identiﬁed,
and the unobserved differences, including differences
in the types of surgeries or trauma types, might affect
the outcomes considered.1972Our study showed that, in the settings of trauma
and complex cardiac surgery, bleeding patients who
subsequently receive allogeneic blood product trans-
fusions have poorer outcomes, which results in higher
costs and longer hospital LOS. Minimizing blood loss
or prompt resolution of bleeding with targeted ther-
apy is likely to reduce additional risks and costs
incurred by patients with trauma or who are under-
going complex cardiac surgery. These concerns are
important both to care providers and to hospital
administrators, whose cost perspectives we took.
These professionals both worry, to varying degrees,
about quality of care and the effects on hospital
ﬁnances. Procedure-related outcomes generating addi-
tional costs and LOS without reimbursement adjust-
ments bode poorly for the ﬁnances of the entire
provider institution. Further, the results of this study
provide break-even estimates for administrators and
clinicians to use when evaluating the costs of therapies
designed to avoid surgical bleeding.
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